Tanzisertib
CAS 899805-25-5
trans-4-((9-((3S)-Tetrahydrofuran-3-yl)-8-((2,4,6-trifluorophenyl)amino)-9H-purin-2-yl)amino)cyclohexanol
4-[[9-[(3S)-oxolan-3-yl]-8-(2,4,6-trifluoroanilino)purin-2-yl]amino]cyclohexan-1-ol
C21-H23-F3-N6-O2, 448.4467
- CC 930
- CC-930
- Tanzisertib
- UNII-M5O06306UO
- A c-Jun amino-terminal kinase inhibitor.UNII, M5O06306UO
Treatment of Idiopathic Pulmonary Fibrosis (IPF)
- Originator Celgene Corporation
- Class Antifibrotics; Small molecules
- Mechanism of ActionJ NK mitogen-activated protein kinase inhibitors
- Orphan Drug Status Yes – Idiopathic pulmonary fibrosis
- Discontinued Discoid lupus erythematosus; Idiopathic pulmonary fibrosis
- 16 Jul 2012 Celgene Corporation terminates a phase II trial in Discoid lupus erythematosus in USA (NCT01466725)
- 23 Feb 2012 Celgene initiates enrolment in a phase II trial for Discoid lupus erythematosus in the USA (NCT01466725)
- 08 Nov 2011The Committee for Orphan Medicinal Products (COMP) recommends orphan drug designation for tanzisertib in European Union for Idiopathic pulmonary fibrosis
Tanzisertib has been granted orphan drug status by the FDA for the treatment of idiopathic pulmonary fibrosis. A positive opinion has been received from the EU Committee for Orphan Medicinal Products (COMP
Tanzisertib has been used in trials studying the treatment of Fibrosis, Discoid Lupus, Pulmonary Fibrosis, Interstitial Lung Disease, and Lung Diseases, Interstitial, among others.
PATENT
https://patents.google.com/patent/US20090048275A1/de
PATENT
WO 2006076595
US 20070060598
WO 2008057252
US 20080021048
US 20140094456
WO 2014055548
PATENT
WO 2015153683
https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2015153683
/////////Tanzisertib, CC 930, Idiopathic Pulmonary Fibrosis, Orphan Drug, phase II, CELGENE
c1c(c(c(cc1F)